Aptinyx APTX shares are trading higher on Tuesday after the company reported Phase 2 clinical data evaluating NYX-783 in PTSD. NYX-783 showed statistically significant and clinically meaningful efficacy results and the company expects to initiate a pivotal study in 2021.
Aptinyx is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel, proprietary, synthetic small molecules for the treatment of brain and nervous system disorders.
Aptinyx shares traded up 43.99% to $5.27 on Tuesday. The stock has a 52-week high of $6.47 and a 52-week low of $1.60.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
